rolistobart

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Non-small Cell Lung CancerNon-small Cell Lung Cancer (NSCLC)non-small cell lung cancer

Phase 2

KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

CompletedCTIS2023-506932-33-00

Merck Sharp & Dohme LLCnon-small cell lung cancer

Start: 2020-10-20End: 2025-09-18Target: 163Updated: 2025-11-14

KEYMAKER-U01 Master Study: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) KEYMAKER-U01 Substudy 2: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Naïve Patients with PD-L1 Positive Advanced Non-small Cell Lung Cancer (NSCLC)

CompletedCTIS2023-506933-32-00

Merck Sharp & Dohme LLCNon-small Cell Lung Cancer (NSCLC)

Start: 2020-10-20End: 2025-10-24Target: 38Updated: 2025-11-11

KEYMAKER-U01 Master Study: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated with anti-PD-(L)1 Therapy

CompletedCTIS2023-506934-56-00

Merck Sharp & Dohme LLCNon-small Cell Lung Cancer

Start: 2020-10-20End: 2025-05-12Target: 45Updated: 2025-06-04